Physician profile
Michael Everett Palmer
NPI 1013253095
$2,102.41
in general payments reported to CMS, 2019-2025
17 companies · $309 in 2025
The $309 reported for 2025 was more than what a typical Physician Assistant provider received nationally (typical 2025 total: $183).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2021: $211 · 2022: $745 · 2023: $484 · 2024: $353 · 2025: $309.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $1,147.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $1,146.75 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Glaxosmithkline, LLC. | $774.00 | 2021-2025 | Trelegy Ellipta, Arexvy, Shingrix |
| Abbvie INC. | $342.52 | 2022-2025 | |
| Boehringer Ingelheim Pharmaceuticals, INC. | $185.81 | 2021-2025 | Jardiance |
| Teva Pharmaceuticals USA, INC. | $143.59 | 2022-2023 | Austedo |
| Medtronic, INC. | $136.65 | 2022 | |
| Novo Nordisk INC | $111.10 | 2021-2025 | Wegovy, Ozempic |
| Bayer Healthcare Pharmaceuticals INC. | $96.99 | 2021-2023 | |
| Vertex Pharmaceuticals Incorporated | $63.55 | 2025 | |
| Catalyst Pharmaceuticals, INC. | $51.67 | 2023 | Fycompa |
| Salix Pharmaceuticals, A Division of Bausch Health US, LLC | $36.88 | 2022-2024 | Xifaxan |
| Exact Sciences Corporation | $28.16 | 2024-2025 | Cologuard Collection Kit |
| Astrazeneca Pharmaceuticals LP | $24.71 | 2024 | Airsupra |
| Sanofi-Aventis U.S. LLC | $24.65 | 2022 | |
| Noven Therapeutics, LLC | $23.94 | 2024 | Secuado, Xelstrym |
| Alk-Abello, INC | $21.86 | 2024 | Odactra, Grastek, Ragwitek |
Show all 17 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Eisai INC. | $20.22 | 2021 | |
| Amgen INC. | $16.11 | 2025 | Otezla, Repatha |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Michael Palmer listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.